Funding for this research was provided by:
European Union’s Horizon 2020 research and innovation programme (Grant Agreement: n° 643708)
Hellenic Foundation for Research and Innovation (HFRI) and the General Secretariat for Research and Technology (466; 133218/Ι2; 04/08/2017)
Text and Data Mining valid from 2020-03-01
Received: 18 November 2019
Accepted: 19 December 2019
First Online: 12 March 2020
Ethics approval and consent to participate
: The Feel4Diabetes-study adhered to the Declaration of Helsinki and the conventions of the Council of Europe on human rights and biomedicine. All participating countries obtained ethical clearance from the relevant ethical committees and local authorities. More specifically, in Belgium the study was approved by the Medical Ethics Committee of the Ghent University Hospital; in Bulgaria, by the Ethics Committee of the Medical University of Varna and the Municipalities of Sofia and Varna, as well as the Ministry of Education and Science local representatives; in Finland, by the hospital district of Southwest Finland ethical committee; in Greece, by the Bioethics Committee of Harokopio University and the Greek Ministry of Education; in Hungary, by the National Committee for Scientific Research in Medicine; and in Spain, by the Clinical Research Ethics Committee and the Department of Consumers’ Health of the Government of Aragón. All participants gave their written informed consent prior to their enrolment in the study.
: Not applicable.
: OA is a member of the Editorial Board of BMC Endocrine Disorders. He also acted as Guest Editor in the current Supplement Issue. None of the rest of the authors has any conflict to declare.